ReviewFrontiers in cardiovascular medicine2026
A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Can Biomarker-Based Monitoring Detect the Early Development of Diastolic Dysfunction During Chemotherapy?Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the first case of an acute ST-segment elevation myocardial infarction (AMI) induced by docetaxel in a patient with triple-negative breast cancer (BC). Coronary angiography showed severe occlusions in multiple coronary arteries, and timely PCI surgery was successfully performed, saving the patient's life. Docetaxel is a commonly used taxane chemotherapy drug for treating breast cancer, which can cause numerous adverse drug reactions in cancer treatment. However, compared with paclitaxel, reports of docetaxel-induced cardiotoxicity are fewer and generally milder, and acute myocardial infarction induced by docetaxel is extremely rare and potentially fatal when it occurs. Due to this severe adverse drug reaction, the subsequent docetaxel chemotherapy regimen was discontinued. In addition, we review this case alongside 12 published case reports and conduct a comprehensive analysis of 94 reported instances of myocardial infarction associated with taxane use from the FDA Adverse Event Reporting System (FAERS) database, evaluating their clinical relevance and key characteristics. In this case, we highly suspect that docetaxel directly caused the acute myocardial infarction, and propose that the mechanism may involve coronary vasospasm, endothelial dysfunction, or prothrombotic effects, although the exact pathway remains unclear. This study, through the rare case of a breast cancer patient who experienced acute myocardial infarction after docetaxel chemotherapy, demonstrates timely and proper cardiac management in a patient assessed as low-risk for cardiotoxicity with no relevant cardiovascular factors. Furthermore, through literature review combined with the FAERS database, we further discuss possible mechanisms, influencing factors, and predictive methods to provide clinical reference and warnings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.